Guidance for Industry

Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions

Annex 12
Analytical Sieving General Chapter

Additional copies are available from:

Office of Communication, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Room 2201
Silver Spring, MD 20993-0002
Phone: 301-796-3400; Fax: 301-847-8714; E-mail: druginfo@fda.hhs.gov

or

Office of Communication, Outreach and Development, HFM-40
Center for Biologics Evaluation and Research
Food and Drug Administration
1401 Rockville Pike, Rockville, MD 20852-1448
(Tel) 800-835-4709 or 301-827-1800

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

September 2010
ICH
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>I.</strong> INTRODUCTION (1) .....................................................................</td>
<td>1</td>
</tr>
<tr>
<td><strong>II.</strong> Q4B OUTCOME (2) ....................................................................</td>
<td>2</td>
</tr>
<tr>
<td>A. Analytical Procedures (2.1) .....................................................</td>
<td>2</td>
</tr>
<tr>
<td>B. Acceptance Criteria (2.2) ................................................................</td>
<td>2</td>
</tr>
<tr>
<td><strong>III.</strong> TIMING OF ANNEX IMPLEMENTATION (3) ...................................</td>
<td>2</td>
</tr>
<tr>
<td><strong>IV.</strong> CONSIDERATIONS FOR IMPLEMENTATION (4) ..................................</td>
<td>2</td>
</tr>
<tr>
<td>A. General Consideration (4.1) .....................................................</td>
<td>2</td>
</tr>
<tr>
<td>B. FDA Consideration (4.2) ................................................................</td>
<td>2</td>
</tr>
<tr>
<td>C. EU Consideration (4.3) ................................................................</td>
<td>2</td>
</tr>
<tr>
<td>D. MHLW Consideration (4.4) ................................................................</td>
<td>3</td>
</tr>
<tr>
<td>E. Health Canada Consideration (4.5) ............................................</td>
<td>3</td>
</tr>
<tr>
<td><strong>V.</strong> REFERENCES USED FOR THE Q4B EVALUATION (5) ..........................</td>
<td>3</td>
</tr>
</tbody>
</table>
I. INTRODUCTION (1)\textsuperscript{2}

This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions. Implementation of the Q4B annexes is intended to avoid redundant testing by industry. For general information on the Q4B process, the reader is referred to the core guidance \textit{Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions}.\textsuperscript{3}

This annex is the result of the Q4B process for the Analytical Sieving General Chapter. The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).

\textsuperscript{1} This guidance was developed within the Expert Working Group (Quality) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and has been subject to consultation by the regulatory parties, in accordance with the ICH process. This document has been endorsed by the ICH Steering Committee at Step 4 of the ICH process, June 2010. At Step 4 of the process, the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan, and the United States.

\textsuperscript{2} Arabic numbers reflect the organizational breakdown of the document endorsed by the ICH Steering Committee at Step 4 of the ICH process, June 2010.

\textsuperscript{3} We update guidance documents periodically. To make sure you have the most recent version of a guidance, check the FDA Drugs guidance page at \url{http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm} or the FDA Biologics guidance page at \url{http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm}. 
FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

II. Q4B OUTCOME (2)

A. Analytical Procedures (2.1)

The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the analytical procedures described in the official pharmacopoeial texts, Ph. Eur. 2.9.38. Particle-size Distribution Estimation by Analytical Sieving, JP 3.04 Particle Size Determination entitled *Method 2. Analytical Sieving Method*, and USP General Chapter <786> Particle Size Distribution Estimation by Analytical Sieving, can be used as interchangeable in the ICH regions.

B. Acceptance Criteria (2.2)

The texts evaluated did not contain acceptance criteria.

III. TIMING OF ANNEX IMPLEMENTATION (3)

When this annex is implemented (incorporated into the regulatory process at ICH Step 5) in a region, it can be used in that region. Timing might differ for each region.

IV. CONSIDERATIONS FOR IMPLEMENTATION (4)

A. General Consideration (4.1)

When sponsors or manufacturers change their existing methods to the implemented Q4B-evaluated pharmacopoeial texts that are referenced in section II.A (2.1) of this annex, any change notification, variation, and/or prior approval procedures should be handled in accordance with established regional regulatory mechanisms pertaining to compendial changes.

B. FDA Consideration (4.2)

Based on the recommendation above, and with reference to the conditions set forth in this annex, the pharmacopoeial texts referenced in section II.A (2.1) of this annex can be considered interchangeable. However, FDA might request that a company demonstrate that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method.

C. EU Consideration (4.3)
For the European Union, regulatory authorities can accept the reference in a marketing authorization application, renewal or variation application citing the use of the corresponding text from another pharmacopoeia as referenced in section II.A (2.1), in accordance with the conditions set out in this annex, as fulfilling the requirements for compliance with the Ph. Eur. Chapter 2.9.38. on the basis of the declaration of interchangeability made above.

D. MHLW Consideration (4.4)

The pharmacopoeial texts referenced in section II.A. (2.1) of this annex can be used as interchangeable in accordance with the conditions set out in this annex. Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented.

E. Health Canada Consideration (4.5)

In Canada any of the texts cited in section II.A (2.1) of this annex and used in accordance with the conditions set out in this annex can be considered interchangeable.

V. REFERENCES USED FOR THE Q4B EVALUATION (5)


B. (5.2) The pharmacopoeial references for Analytical Sieving General Chapter for this annex are:

